1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Immucor, Inc. ( Immucor  and, together with its wholly owned subsidiaries, the  Company ) develops, manufactures and sells a complete line of reagents and automated systems used primarily by hospitals, donor centers and reference laboratories in a number of tests performed to detect and identify certain properties of human blood for the purpose of blood transfusion. The Company distributes its products globally through both direct affiliate offices and third-party distribution arrangements. Basis of Presentation The Company was acquired on August 19, 2011 through a merger transaction with IVD Acquisition Corporation ( Merger Sub ), a wholly owned subsidiary of IVD Intermediate Holdings B, Inc. (the  Parent ). The Parent is a wholly owned indirect subsidiary of IVD Holdings, Inc. which was formed by investment funds affiliated with TPG Capital, L.P. ( TPG Capital ). The acquisition was accomplished through a merger of the Merger Sub with and into Immucor, with Immucor being the surviving company (the  Acquisition ). As a result of the merger, Immucor became a wholly owned subsidiary of Parent. Prior to August 19, 2011, Immucor operated as a public company with common stock traded on the NASDAQ Stock Market. Immucor continued as the same legal entity after the Acquisition. However, a new accounting basis was established upon treating the merger as a business combination. The accompanying unaudited condensed consolidated statements of operations, comprehensive loss, and cash flows are presented for the quarter ended August 31, 2012 and the quarter ended August 31, 2011, which is presented in two periods: the Predecessor fiscal 2012 period (June 1, 2011 to August 19, 2011) and the Successor fiscal 2012 period (August 20, 2011 to August 31, 2011), which relate to the period preceding the Acquisition and the period succeeding the Acquisition during the prior fiscal year. Although the accounting policies followed by the Company are consistent for the Pre